A PYXAX editorial reference. Source review: October 22, 2026.
The classification dispute concerns an approval pathway. It does not establish who may sell a separately sourced research material.
Eli Lilly sought to have retatrutide classified as a biological product. In an October 2, 2026 letter, FDA again rejected that position and said an application would need to follow section 505 of the Federal Food, Drug, and Cosmetic Act. The agency was explaining its decision after a court remand, not announcing its first response to Lilly. FDA remand letter, pages 1–2.
The retatrutide classification argument turns on the structure the regulatory definition counts. A 39-residue chain is central to FDA’s reasoning, but the side-chain analysis matters too.
Scope: selected public documents dated September 30, 2025–October 8, 2026, rechecked October 22, 2026. This explains those records, not the complete current docket or a final appellate outcome. It is not legal advice.
Which parts count under FDA’s definition?
For this classification, the regulatory protein definition requires a specified sequence longer than 40 amino acids. FDA reads that size requirement as referring to alpha amino acids. The distinction affects whether parts of retatrutide’s side chain can be added to its 39-alpha-amino-acid chain. FDA letter, pages 2–3 and 10–13.
FDA identifies ADO, gamma-glutamate and a fatty-acid component in the side chain. Its reasoning does not dismiss gamma-glutamate as a non-alpha amino acid. It recognizes gamma-glutamate as an alpha amino acid, but finds that it and ADO do not form another chain of alpha amino acids: ADO is an amino acid, but not an alpha amino acid. Even hypothetically counting the extra gamma-glutamate would yield 40, still short of the greater-than-40 requirement. FDA letter, pages 11–12, including footnote 48.
The 39-residue description refers to the chain used in FDA’s classification analysis. It does not mean that the other chemical components are absent.
Why FDA was answering again
The Southern District of Indiana’s September 30, 2025 order addressed two routes to biological-product classification. It upheld FDA’s determination under the protein definition, but vacated and remanded the separate determination about a product analogous to a protein. The court did not itself order biological-product designation. District order, pages 12–16.
On remand, FDA explained the minimum characteristics it considers necessary for that analogous-product category and again found retatrutide outside it. That was the agency’s renewed analysis; it was not a final appellate judgment. FDA letter, pages 5–13.
Why the earlier label matters
The letter also points to Lilly’s earlier description of the related molecule tirzepatide as a 39-amino-acid peptide with an attached linker. FDA uses that description in explaining its analysis of ADO. It supplies context for the agency’s reasoning, not proof of a company’s motive or a finding that the two molecules have identical properties. FDA letter, pages 11–12.
The appeal raised a separate jurisdiction question
In appeal 26-1301, the Seventh Circuit’s September 24, 2026 order directed supplemental memoranda on appellate jurisdiction over this type of agency-remand order. Lilly’s October 8 brief argued that jurisdiction existed and addressed FDA’s remand decision. A party’s brief records its position; it does not establish that the court accepted it. Appellate order, document 45; Lilly supplemental brief, document 47.
What this record does not establish
The letter is not an approval of retatrutide, a certificate for an independently supplied vial, or permission to use research material in humans. This account makes no claim about an ultimate appellate disposition, exclusivity outcome or blanket permission for a research supplier to sell material.
Regulatory category, molecular identity and lot-specific analytical results answer different questions. The court-filed letter helps explain the first. A particular material’s identity and measured characteristics require their own evidence.
PYXAX’s verification scope
PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.
The verification panel concerns the batch record. It does not supply regulatory authorization, characterize another supplier’s material or establish suitability for human use.
All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.